You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy

    SBC: Enzyme by Design Inc.            Topic: 102

    PROJECT SUMMARY Enzyme by DesignIncEbDis developing a safer version of L asparaginase that can be used routinely in the treatment of adult ALL patients whose hypersensitivity to todayandapos s bacterial L asparaginases deprives them from this efficacious therapyEbDandapos s L asparaginase is novel due to its mammalianguinea pigorigin and its lack of L glutaminase co activityThe need for better the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Optimization of Novel Ryanodine Receptor Modulatory Compounds for Alzheimer's Disease

    SBC: NeuroLucent            Topic: NIA

    Abstract Summary Currentlythere are no effective treatments to preserve cognitive function in AD patients and the recent series of disappointing clinical trials highlight the need to explore alternative pathwaysTo this endNeuroLucent Incand its academic partnerRFUMSare developing small molecule compounds designed as allosteric modulators of the ryanodine receptorRyRa high conductance calcium chann ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Robot-Assisted Cognitive Training for Socially Isolated Older Adults with Mild Cognitive Impairment

    SBC: Applied Universal Dynamics, Corp.            Topic: NIA

    Project Summary Abstract This project will develop a Socially Assistive RobotSARto provide cognitive trainingin the form of learning to play the pianoto improve cognitive functioning and reduce feelings of loneliness in socially isolated older adultsThe SAR will administer cognitive training via guided practice on a set of standard piano lesson tasks designed to reflect particular cognitive functi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of mitochondrial disease mouse models

    SBC: B-MoGen Biotechnologies Inc            Topic: OD

    Project Abstract Mitochondria are double membrane bound organelles that are found in all eukaryotic cells and carry a specialized circularkb genomeThere is a group of devastating human genetic diseases caused by inherited or spontaneous mutation of genes encoded within the mitochondrial genomeThese diseases can cause a wide array of medical problems from subtle muscular weakness to extreme neuromu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Wireless Implantable Neural Recording Device

    SBC: Neurolux, Inc.            Topic: 105

    Project Summary NeuroLux Increcently developed and commercialized a fully implantablewireless optogeneticLED stimulator that istimes smaller by volume andtimes lighter in weight than current state of the art methodologywww neurolux org productsWith this technologythe neural circuitry of an unrestrictedfreely moving animal can be manipulated on demandallowing us to study the dynamic effects of neur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government